{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:53:51Z","timestamp":1793332431961,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1475-2875-13-363","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T11:05:41Z","timestamp":1410779141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania"],"prefix":"10.1186","volume":"13","author":[{"given":"Amani T","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Ngalesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole F","family":"Norheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Robberstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,15]]},"reference":[{"key":"3392_CR1","volume-title":"World Malaria Report","author":"WHO","year":"2013","unstructured":"WHO: World Malaria Report. 2013, Geneva: World Health Organization"},{"key":"3392_CR2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"CJ Murray","year":"2012","unstructured":"Murray CJ, Global Burden of Disease Study Group: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380: 2197-2223. 10.1016\/S0140-6736(12)61689-4.","journal-title":"Lancet"},{"key":"3392_CR3","volume-title":"Malaria and Children: Progress in intervention coverage","author":"UNICEF, RBM","year":"2007","unstructured":"UNICEF, RBM: Malaria and Children: Progress in intervention coverage. 2007, New York: United Nations Children's Fund and Roll Back Malaria"},{"key":"3392_CR4","volume-title":"Guidelines for the Treatment of Malaria","author":"WHO","year":"2010","unstructured":"WHO: Guidelines for the Treatment of Malaria. 2010, Geneva: World Health Organization, 2","edition":"2"},{"key":"3392_CR5","first-page":"CD007483","volume":"3","author":"D Sinclair","year":"2009","unstructured":"Sinclair D, Zani B, Donegan S, Olliaro P, Garner P: Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009, 3: CD007483-","journal-title":"Cochrane Database Syst Rev"},{"key":"3392_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/trstmh\/trs019","volume":"107","author":"C Naing","year":"2012","unstructured":"Naing C, Mak JW, Aung K, Wong J: Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomized controlled trials. Trans R Soc Trop Med Hyg. 2012, 107: 65-73.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3392_CR7","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1371\/journal.pctr.0020020","volume":"2","author":"MR Kamya","year":"2007","unstructured":"Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007, 2: e20-10.1371\/journal.pctr.0020020.","journal-title":"PLoS Clin Trials"},{"key":"3392_CR8","doi-asserted-by":"publisher","first-page":"e2390","DOI":"10.1371\/journal.pone.0002390","volume":"3","author":"A Yeka","year":"2008","unstructured":"Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One. 2008, 3: e2390-10.1371\/journal.pone.0002390.","journal-title":"PLoS One"},{"key":"3392_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1475-2875-10-50","volume":"10","author":"M Nambozi","year":"2011","unstructured":"Nambozi M, Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, Ubben D, D'Alessandro U: Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated plasmodium falciparum malaria in Zambian children. Malar J. 2011, 10: 50-10.1186\/1475-2875-10-50.","journal-title":"Malar J"},{"key":"3392_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.trstmh.2006.01.001","volume":"100","author":"C Karema","year":"2006","unstructured":"Karema C, Fanello CI, Overmeir CV, JP V g, van Doren W, Ngamije D, D'Alessandro U: Safety and efficacy of dihydroartemisinin\/piperaquine (Artekin\u00ae) for the treatment of uncomplicated plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006, 100: 1105-1111. 10.1016\/j.trstmh.2006.01.001.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3392_CR11","doi-asserted-by":"publisher","first-page":"e7871","DOI":"10.1371\/journal.pone.0007871","volume":"4","author":"Q Bassat","year":"2009","unstructured":"Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Mene\u2019ndez C, Nambozi M, Vale\u2019a I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D\u2019Alessandro U: Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in african children: a randomised, non-inferiority trial. PLoS One. 2009, 4: e7871-10.1371\/journal.pone.0007871.","journal-title":"PLoS One"},{"key":"3392_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1179\/136485910X12743554760144","volume":"104","author":"I Adam","year":"2010","unstructured":"Adam I, Salah MT, Eltahir HG, Elhassan AH, Elmardi KA, Malik EM: Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated plasmodium falciparum malaria in central Sudan. Ann Trop Med Parasitol. 2010, 104: 319-326. 10.1179\/136485910X12743554760144.","journal-title":"Ann Trop Med Parasitol"},{"key":"3392_CR13","doi-asserted-by":"publisher","first-page":"e1001119","DOI":"10.1371\/journal.pmed.1001119","volume":"8","author":"The Four Artemisinin-Based Combinations (4ABC) Study Group","year":"2011","unstructured":"The Four Artemisinin-Based Combinations (4ABC) Study Group: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in african children: a randomized trial. PLoS Med. 2011, 8: e1001119-10.1371\/journal.pmed.1001119.","journal-title":"PLoS Med"},{"key":"3392_CR14","volume-title":"National Guidelines for Malaria Diagnosis and Treatment","author":"Ministry of Health and Social Welfare","year":"2006","unstructured":"Ministry of Health and Social Welfare: National Guidelines for Malaria Diagnosis and Treatment. 2006, Dar es Salaam: National Malaria Control Programme"},{"key":"3392_CR15","volume-title":"Standard Treatment Guidelines and National Essential Medicine List-Tanzania Mainland","author":"Ministry of Health and Social Welfare","year":"2013","unstructured":"Ministry of Health and Social Welfare: Standard Treatment Guidelines and National Essential Medicine List-Tanzania Mainland. 2013, Dar es Salaam: Ministry of Health and Social Welfare, 4","edition":"4"},{"key":"3392_CR16","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1371\/journal.pmed.0030373","volume":"3","author":"V Wiseman","year":"2006","unstructured":"Wiseman V, Kim M, Mutabingwa TK, Whitty CJ: Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Med. 2006, 3: e373-10.1371\/journal.pmed.0030373.","journal-title":"PLoS Med"},{"key":"3392_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1475-2875-6-21","volume":"6","author":"P Chanda","year":"2007","unstructured":"Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Hawela M, Banda P, Okorosobo T: A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia. Malar J. 2007, 6: 21-10.1186\/1475-2875-6-21.","journal-title":"Malar J"},{"key":"3392_CR18","doi-asserted-by":"publisher","first-page":"e95681","DOI":"10.1371\/journal.pone.0095681","volume":"9","author":"J Pfeil","year":"2014","unstructured":"Pfeil J, Borrmann S, Tozan Y: Dihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in african children: a cost-effectiveness analysis. PLoS One. 2014, 9: e95681-10.1371\/journal.pone.0095681.","journal-title":"PLoS One"},{"key":"3392_CR19","volume-title":"Guidelines for Case Management of Malaria in Ghana","author":"Ministry of Health","year":"2009","unstructured":"Ministry of Health: Guidelines for Case Management of Malaria in Ghana. 2009, Accra: Ministry of Health, 2","edition":"2"},{"key":"3392_CR20","volume-title":"National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya","author":"Ministry of Public Health and Sanitation","year":"2010","unstructured":"Ministry of Public Health and Sanitation: National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya. 2010, Nairobi: Ministry of Public Health and Sanitation, 3","edition":"3"},{"key":"3392_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7175\/fe.v14i1.638","volume":"14","author":"AT Mori","year":"2013","unstructured":"Mori AT, Gavaza P, Robberstad B: The role of pharmacoeconomics in developing countries. Farmeconomia. Health Economics and Therapeutic Pathways. 2013, 14: 3-5.","journal-title":"Farmeconomia. Health Economics and Therapeutic Pathways"},{"key":"3392_CR22","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1128\/IAI.72.11.6538-6545.2004","volume":"72","author":"ML Gatton","year":"2004","unstructured":"Gatton ML, Cheng Q: Modeling the development of acquired clinical immunity to plasmodium falciparum malaria. Infect Immun. 2004, 72: 6538-6545. 10.1128\/IAI.72.11.6538-6545.2004.","journal-title":"Infect Immun"},{"key":"3392_CR23","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1126\/science.8009217","volume":"264","author":"LH Miller","year":"1994","unstructured":"Miller LH, Good MF, Milon G: Malaria pathogenesis. Science. 1994, 264: 1878-1884. 10.1126\/science.8009217.","journal-title":"Science"},{"key":"3392_CR24","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes. 2005, New York: Oxford University Press, 3","edition":"3"},{"key":"3392_CR25","first-page":"XLIV","volume-title":"Economic Bulletin for the Quarter Ending December 2012","author":"Bank of Tanzania","year":"2012","unstructured":"Bank of Tanzania: Economic Bulletin for the Quarter Ending December 2012. 2012, Economic Bulletin, XLIV-"},{"key":"3392_CR26","volume-title":"Cost Analysis in Primary Health Care: A training Manual for Programme Managers","author":"WHO","year":"1994","unstructured":"WHO: Cost Analysis in Primary Health Care: A training Manual for Programme Managers. 1994, Geneva: World Health Organization"},{"key":"3392_CR27","unstructured":"Medical Stores Department: Price Catalogue of Essential Medicines, Diagnostics and Hospital Supplies-2011\/2012. Dar es Salaam: Medical Stores Department"},{"key":"3392_CR28","volume-title":"Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis","author":"WHO","year":"2003","unstructured":"WHO: Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. 2003, Geneva: World Health Organization"},{"key":"3392_CR29","volume-title":"ACT Prices under the Affordable Medicines Facility-malaria: Update of 22 May 2013","author":"The Global Fund","year":"2013","unstructured":"The Global Fund: ACT Prices under the Affordable Medicines Facility-malaria: Update of 22 May 2013. 2013, Geneva, Switzerland: The Global Fund"},{"key":"3392_CR30","volume-title":"Application for Inclusion of Dihydroartemisinin\/Piperaquine in the 17th WHO Model List of Essential Medicines","author":"SA Sigma-Tau","year":"2010","unstructured":"Sigma-Tau SA: Application for Inclusion of Dihydroartemisinin\/Piperaquine in the 17th WHO Model List of Essential Medicines. 2010"},{"key":"3392_CR31","volume-title":"International Drug Price Indicator Guide","author":"Management Science for Health","year":"2012","unstructured":"Management Science for Health: International Drug Price Indicator Guide. 2012, Arlington, USA: Management Science for Health, Inc, 2011","edition":"2011"},{"key":"3392_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-7547-1-1","volume":"1","author":"B Johns","year":"2003","unstructured":"Johns B, Baltussen R, Hutubessy R: Programme costs in the economic evaluation of health interventions. Cost Effect Resource Alloc. 2003, 1: 1-10.1186\/1478-7547-1-1.","journal-title":"Cost Effect Resource Alloc"},{"key":"3392_CR33","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Global Burden of Disease Group: Common values in assessing health outcomes from diseases and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012, 380: 2129-2143. 10.1016\/S0140-6736(12)61680-8.","journal-title":"Lancet"},{"key":"3392_CR34","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/heapol\/16.3.326","volume":"16","author":"JA Fox-Rushby","year":"2001","unstructured":"Fox-Rushby JA, Hanson K: Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan. 2001, 16: 326-331. 10.1093\/heapol\/16.3.326.","journal-title":"Health Policy Plan"},{"key":"3392_CR35","volume-title":"World Health Statistics 2012: Life Tables for WHO Member States","author":"WHO","year":"2012","unstructured":"WHO: World Health Statistics 2012: Life Tables for WHO Member States. 2012, Geneva: World Health Organization"},{"key":"3392_CR36","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, Vugt M, Nosten F, Looareesuwan S, White NJ: Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000, 44: 697-704. 10.1128\/AAC.44.3.697-704.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"3392_CR37","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1128\/AAC.02318-13","volume":"58","author":"J Tarning","year":"2014","unstructured":"Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, White NJ, Nosten F, Day NPJ: Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother. 2014, 58: 2052-2058. 10.1128\/AAC.02318-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"3392_CR38","first-page":"CD010927","volume":"1","author":"B Zani","year":"2014","unstructured":"Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D: Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014, 1: CD010927-","journal-title":"Cochrane Database Syst Rev"},{"key":"3392_CR39","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4269\/ajtmh.2004.71.196","volume":"7","author":"P Coleman","year":"2004","unstructured":"Coleman P, Morel C, Shillcut S, Goodman C, Mills A: A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-Saharan Africa. Am J Trop Med Hyg. 2004, 7: 196-204.","journal-title":"Am J Trop Med Hyg"},{"key":"3392_CR40","first-page":"61","volume-title":"Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance","author":"Committee on the Economics of Antimalarial Drugs, Board on Global Health","year":"2004","unstructured":"Committee on the Economics of Antimalarial Drugs, Board on Global Health: The cost and cost-effectiveness of antimalarial drugs. Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Edited by: Arrow KJ, Panosian CB, Gelband H. 2004, Washngton, DC: National Academies Press, 61-78."},{"key":"3392_CR41","volume-title":"Economic Analysis of Malaria Control in Sub-Saharan Africa","author":"C Goodman","year":"2000","unstructured":"Goodman C, Coleman P, Mills A: Economic Analysis of Malaria Control in Sub-Saharan Africa. 2000, Geneva: Global Forum for Health Research"},{"key":"3392_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2875-13-7","volume":"13","author":"K Banek","year":"2014","unstructured":"Banek K, Lalani M, Staedke SG, Chandramohan D: Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014, 13: 7-10.1186\/1475-2875-13-7.","journal-title":"Malar J"},{"key":"3392_CR43","doi-asserted-by":"publisher","first-page":"e84555","DOI":"10.1371\/journal.pone.0084555","volume":"9","author":"K Bruxvoort","year":"2014","unstructured":"Bruxvoort K, Goodman C, Kachur SP, Schellenberg D: How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS One. 2014, 9: e84555-10.1371\/journal.pone.0084555.","journal-title":"PLoS One"},{"key":"3392_CR44","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1365-3156.2009.02289.x","volume":"14","author":"N Beer","year":"2009","unstructured":"Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy AH, Bjo\u00a8rkman A, Ka\u00a8llander K: Adherence to artesunate\u2013amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Inter Health. 2009, 14: 766-774. 10.1111\/j.1365-3156.2009.02289.x.","journal-title":"Trop Med Inter Health"},{"key":"3392_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4269\/ajtmh.2012.11-0047","volume":"86","author":"A Ratsimbasoa","year":"2012","unstructured":"Ratsimbasoa A, Ravony H, Vonimpaisomihanta JA, Raherinjafy R, Jahevitra M, Rapelanoro R, Rakotomanga JM, Malvy D, Millet P, M\u00e9nard D: Compliance, safety, and effectiveness of fixed-dose artesunate-amodiaquine for presumptive treatment of non-severe malaria in the context of home management of malaria in Madagascar. Am J Trop Med Hyg. 2012, 86: 203-210. 10.4269\/ajtmh.2012.11-0047.","journal-title":"Am J Trop Med Hyg"},{"key":"3392_CR46","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1214482","volume":"370","author":"V D\u2019Acremont","year":"2014","unstructured":"D\u2019Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama J, Lengeler C, Cherpillod P, Kaiser L, Genton B: Beyond malaria \u2014 causes of fever in outpatient Tanzanian children. N Engl J Med. 2014, 370: 809-817. 10.1056\/NEJMoa1214482.","journal-title":"N Engl J Med"},{"key":"3392_CR47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1475-2875-4-55","volume":"4","author":"K Mugittu","year":"2005","unstructured":"Mugittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, Beck H, Genton B: Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. Malar J. 2005, 4: 55-10.1186\/1475-2875-4-55.","journal-title":"Malar J"},{"key":"3392_CR48","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(05)66417-3","volume":"365","author":"TK Mutabingwa","year":"2005","unstructured":"Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine\u2009+\u2009sulfadoxine-pyrimethamine, amodiaquine\u2009+\u2009artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005, 365: 1474-1480. 10.1016\/S0140-6736(05)66417-3.","journal-title":"Lancet"},{"key":"3392_CR49","volume-title":"World Health Statistics","author":"WHO","year":"2012","unstructured":"WHO: World Health Statistics. 2012, Geneva: World Health Organization"},{"key":"3392_CR50","volume-title":"HIV\/AIDS and Malaria Indicator Survey 2011\u20132012","author":"Tanzania Commission for AIDS, Zanzibar AIDS Commission, National Bureau of Statistics, The Chief Government Statistician, ICF International:","year":"2013","unstructured":"Tanzania Commission for AIDS, Zanzibar AIDS Commission, National Bureau of Statistics, The Chief Government Statistician, ICF International:: HIV\/AIDS and Malaria Indicator Survey 2011\u20132012. 2013, Dar es Salaam: TACAIDS, ZAC, NBS, OCGS and ICF International"},{"key":"3392_CR51","doi-asserted-by":"publisher","first-page":"e17439","DOI":"10.1371\/journal.pone.0017439","volume":"6","author":"Y Lubell","year":"2011","unstructured":"Lubell Y, Staedke SG, Greenwood BM, Kamya MR, Molyneux M, Newton PN, Reyburn H, Snow RW, D\u2019Alessandro U, English M, Day N, Kremsner P, Dondorp A, Mbacham W, Dorsey G, Owusu-Agyei S, Maitland K, Krishna S, Newton C, Pasvol G, Taylor T, von Seidlein L, White NJ, Binka F, Mills A, Whitty CJ: Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models: a Delphi survey. PLoS One. 2011, 6: e17439-10.1371\/journal.pone.0017439.","journal-title":"PLoS One"},{"key":"3392_CR52","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","volume":"13","author":"AM Dondorp","year":"2010","unstructured":"Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Amumpaire JM, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, for the AQUAMAT group: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010, 13: 1647-1657.","journal-title":"Lancet"},{"key":"3392_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1475-2875-3-27","volume":"3","author":"D De Savigny","year":"2004","unstructured":"De Savigny D, Mayombana C, Mwageni E, Masanja H, Minhaj A, Mkilindi Y, Mbuya C, Kasale H, Reid G: Care-seeking patterns for fatal malaria in Tanzania. Malar J. 2004, 3: 27-10.1186\/1475-2875-3-27.","journal-title":"Malar J"},{"key":"3392_CR54","volume-title":"Making choices in health care: WHO guide to cost-effectiveness analysis","author":"E Tan-Torres","year":"2003","unstructured":"Tan-Torres E, Baltussen R, Adam T RH, Acharya A, Evans DB, Murray CJ: Making choices in health care: WHO guide to cost-effectiveness analysis. 2003, Geneva: World Health Organization"},{"key":"3392_CR55","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/10899580-000000000-00000","volume":"27","author":"SD Shillcutt","year":"2009","unstructured":"Shillcutt SD, Walker DG, Goodman CA, Mills AJ: Cost-effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009, 27: 903-917. 10.2165\/10899580-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"3392_CR56","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/bmj.39073.496829.AE","volume":"334","author":"H Reyburn","year":"2007","unstructured":"Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Chris Drakeley C, Whitty CJM: Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ. 2007, 334: 403-10.1136\/bmj.39073.496829.AE.","journal-title":"BMJ"},{"key":"3392_CR57","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Claxton K, Sculpher M: Decision Modelling for Health Economic Evaluation. 2006, Oxford: Oxford University Press"},{"key":"3392_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/0272989X9401400308","volume":"14","author":"SB Cantor","year":"1994","unstructured":"Cantor SB: Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994, 14: 259-265. 10.1177\/0272989X9401400308.","journal-title":"Med Decis Making"},{"key":"3392_CR59","volume-title":"World Health Report","author":"WHO","year":"2002","unstructured":"WHO: World Health Report. 2002, Geneva, Switzerland: World Health Organization"},{"key":"3392_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/1475-2875-12-211","volume":"12","author":"D Ubben","year":"2013","unstructured":"Ubben D, Poll EM: MMV in partnership: the Eurartesim experience. Malar J. 2013, 12: 211-10.1186\/1475-2875-12-211.","journal-title":"Malar J"},{"key":"3392_CR61","volume-title":"Eurartesim\u00ae: Stamp of approval from the European Medicines Agency","author":"Medicines for Malaria Venture","year":"2011","unstructured":"Medicines for Malaria Venture: Eurartesim\u00ae: Stamp of approval from the European Medicines Agency. 2011, Available on: http:\/\/www.mmv.org\/achievements-challenges\/achievements\/eurartesim\u00ae"},{"key":"3392_CR62","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1086\/647946","volume":"49","author":"E Arinaitwe","year":"2009","unstructured":"Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis. 2009, 49: 1629-1637. 10.1086\/647946.","journal-title":"Clin Infect Dis"},{"key":"3392_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2875-7-9","volume":"7","author":"NJ White","year":"2008","unstructured":"White NJ: How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 2008, 7: 9-10.1186\/1475-2875-7-9.","journal-title":"Malar J"},{"key":"3392_CR64","doi-asserted-by":"publisher","first-page":"e1001564","DOI":"10.1371\/annotation\/3db421e4-3e27-4442-8092-2ad1b778f371","volume":"10","author":"The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group","year":"2013","unstructured":"The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group: The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013, 10: e1001564-10.1371\/journal.pmed.1001564.","journal-title":"PLoS Med"},{"key":"3392_CR65","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1128\/AAC.00486-07","volume":"51","author":"RN Price","year":"2007","unstructured":"Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E: Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother. 2007, 51: 4090-4097. 10.1128\/AAC.00486-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"3392_CR66","volume-title":"World Malaria Report","author":"WHO","year":"2011","unstructured":"WHO: World Malaria Report. 2011, Geneva: World Health Organization"},{"key":"3392_CR67","doi-asserted-by":"publisher","first-page":"e1000301","DOI":"10.1371\/journal.pmed.1000301","volume":"7","author":"PW Gething","year":"2010","unstructured":"Gething PW, Kirui VC, Alegana VA, Okiro EA, Noor AM, Snow RW: Estimating the number of paediatric fevers associated with malaria infection presenting to Africa\u2019s public health sector in 2007. PLoS Med. 2010, 7: e1000301-10.1371\/journal.pmed.1000301.","journal-title":"PLoS Med"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2875-13-363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T13:54:16Z","timestamp":1717336456000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/1475-2875-13-363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1186\/1475-2875-13-363","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,15]]},"assertion":[{"value":"7 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"363"}}